(Adnkronos) - Si è svolto a Milano l’evento con il quale è stata presentata una nuova opzione terapeutica per i pazienti con artrite psoriasica attiva, una condizione infiammatoria sistemica cronica grave, altamente eterogenea, che colpisce sia le articolazioni sia la pelle e che in Italia riguarda oltre 100mila persone. Si tratta di bimekizumab, sviluppato da Ucb Pharma, al quale Aifa ha concesso l’estensione di rimborsabilità per l’artrite psoriasica attiva, dopo quella ottenuta nel marzo 2023 per la psoriasi a placche da moderata a severa.
Category
🗞
NewsTranscript
00:00It affects more than 100,000 people in Italy, with prevalence between 30 and 50 years and without gender differences,
00:06limiting mobility due to joint pain and swelling and impacting quality of life.
00:11It is active psoriasis arthritis, a chronic and serious systemic inflammatory condition
00:16that affects both joints and skin.
00:19Thanks to the free route of AIFA, the extension of reimbursability of the monoclonal antibiotic bimechizumab for this pathology,
00:25after having granted it in 2023 for psoriasis plaque from moderate to severe,
00:29patients suffering from active psoriasis arthritis will be able to take advantage of a new therapeutic option
00:34able to offer a high level of disease control in skeletal and cutaneous muscle failures.
00:40Bimechizumab is a monoclonal antibody that links two fundamental inflammatory factors for the development of the disease,
00:48which are interleukin A17 and F.
00:51It was finally approved also for psoriasis arthritis
00:55and therefore we can block both the progression from psoriasis to arthritis,
01:03but also the pain and the arthritis itself, using a single drug that blocks two inflammatory factors.
01:12To confirm the effectiveness, tolerability and safety of the monoclonal antibody in the treatment of active psoriasis arthritis,
01:19the results at 52 weeks of the B-Complete B-Vital open extension study,
01:23based on the data at 16 weeks of the B-Complete study and on those at 52 weeks of the B-Optimal study.
01:30The long-term data show that more than 6 patients out of 10 treated continuously with bimechizumab
01:36have obtained a complete cutaneous clearance and almost 1 in 2 had a minimal disease activity at the 52nd week.
01:44From an rheumatological point of view, the most interesting result is linked to the number of patients
01:50who achieve a result called MDA, that is Minimal Disease Activity.
01:54This MDA, which is a situation very close to complete remission,
01:59is achieved in a very high percentage of patients,
02:02so this gives us great hope in real life to achieve the same result in the patients we see in the clinic.
02:08The introduction of this biological therapy in the range of treatment options available to clinicians
02:13gives patients the hope of a better quality of life.
02:17UCB Pharma has been doing research in various fields for almost 100 years,
02:22but lately it has concentrated its research in immunology and neurology.
02:27Last year it invested almost 30% of its turnover, which is 5.3 billion, in research and development,
02:35and we do it with a precision research based on antibodies and small molecules.
02:40It is a commitment that has certainly already yielded great results,
02:44this is a very important indication that we are launching today,
02:48but it will go on and, in short, new answers should really come
02:53for the needs of patients who are still not satisfied.